Frazier Life Sciences Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-4,345,559
| Closed | -$167M | – | 55 |
|
|
2023
Q2 | $167M | Hold |
4,345,559
| – | – | 9.97% | 2 |
|
|
2023
Q1 | $101M | Hold |
4,345,559
| – | – | 7.28% | 3 |
|
|
2022
Q4 | $114M | Buy |
4,345,559
+80,000
| +2% | +$2.1M | 7.08% | 4 |
|
|
2022
Q3 | $83.9M | Buy |
4,265,559
+670,533
| +19% | +$13.2M | 6.46% | 4 |
|
|
2022
Q2 | $62.9M | Buy |
3,595,026
+882,985
| +33% | +$15.4M | 5.93% | 5 |
|
|
2022
Q1 | $44.4M | Buy |
+2,712,041
| New | +$44.4M | 3.78% | 9 |
|